Orphan drugs to grow twice as fast as rest of the industry: report

Research from EvaluatePharma predicts the orphan drug market will grow 11% each year to 2024.

Accenture faces 'conflict of interest' questions over buying programmatic, auditing media

Specialist media consulting firms and media agencies have claimed Accenture faces a "clear conflict" of interest over the launch of its programmatic media planning and ...

Analysts: J&J doesn't need to worry about Sun Pharma's prostate cancer drug

Sun Pharma's branded prostate cancer treatment Yonsa just received FDA approval.

How data regulation could be good for marketing post-Cambridge Analytica

How data regulation could be good for marketing post-Cambridge Analytica

Stuart Ingis on the benefits of showing the public how advertisers and marketers use data and creating a global regulatory framework.

Experts skeptical feds' move on Insys will tilt scales of justice against opioid maker

Experts skeptical feds' move on Insys will tilt scales of justice against opioid maker

Insys founder John Kapoor has maintained his innocence in the face of charges.

MM&M Hall of Femme 2018: The profiles

MM&M Hall of Femme 2018: The profiles

MM&M is honoring 15 of the most-senior women in healthcare along with 20 Women to Watch who are changing the industry.

Five things for pharma marketers to know: Friday, May 25, 2018

Five things for pharma marketers to know: Friday, May 25, 2018

AstraZeneca lung cancer drug meets key goal; Johnson & Johnson loses another talc lawsuit; Cancer drugs account for 80% of drug sales.

GDPR: How to make sure your business is ready

GDPR: How to make sure your business is ready

As of May 25, Europe's groundbreaking General Data Protection Regulation (GDPR) will take effect, fundamentally changing the way businesses and government agencies deal with personal data.

VIDEO: Here's how Publicis Groupe's AI-powered Marcel will look and work

VIDEO: Here's how Publicis Groupe's AI-powered Marcel will look and work

Publicis Groupe unveiled its much-anticipated AI-powered platform Marcel at its VivaTech event this morning in Paris.

Five things for pharma marketers to know: Thursday, May 24, 2018

Five things for pharma marketers to know: Thursday, May 24, 2018

Recro non-opioid injection receives complete response letter from FDA; Pfizer settles False Claims Act allegations; Medtronic reports better-than-expected profit.

4As O'Brien: How healthcare marketing has changed under Trump

4As O'Brien: How healthcare marketing has changed under Trump

Speakers at the Coalition for Healthcare Communication conference discussed how regulations from the White House and FDA have affected healthcare comms.

Accenture Interactive launches programmatic unit in response to 'significant' client demand

Accenture Interactive launches programmatic unit in response to 'significant' client demand

Accenture has taken another big step into the agency space by launching a programmatic media planning and buying unit.

Five things for pharma marketers to know on Wednesday, May 23, 2018

Five things for pharma marketers to know on Wednesday, May 23, 2018

Keytruda passes late-stage trial; Astellas to cut 600 jobs in restructuring; Teva expects FDA decision on migraine drug by mid-September.

Health diagnostic startup Nanobiosym brings on Finn Partners as AOR

Health diagnostic startup Nanobiosym brings on Finn Partners as AOR

Nanobiosym hired the agency shortly after its proprietary technology was approved by the FDA.

Five things for pharma marketers to know: Tuesday, May 22, 2018

Five things for pharma marketers to know: Tuesday, May 22, 2018

Geisinger looks to expand DNA sequencing program; Celgene invests $65 million more in Evotec; Oscar launches transparency push.

Plan D: Experts predict government savings, but higher co-pays with Trump plan for lowering drug prices

Plan D: Experts predict government savings, but higher co-pays with Trump plan for lowering drug prices

The White House's strategy calls for moving expensive treatments from under Medicare Part B to Medicare Part D.